NICE has published single technology appraisal guidance (STA) for the only licensed biologic medicine, Humira® (adalimumab), for the treatment of the skin condition hidradenitis suppurativa (HS).
NICE’s approval for HS (also known as acne inversa) means that patients in England and Wales deemed clinically appropriate now have the right to access this treatment via the NHS.
Adalimimab is recommended as an option for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
HS affects around a million people in the UK. Sufferers experience recurrent, painful abscesses and nodules (boil-like lumps) in specific areas of the body including the groin and underarm which are often very uncomfortable, painful and can lead to scarring.